BioCentury
ARTICLE | Clinical News

XF-73 regulatory update

November 23, 2015 8:00 AM UTC

FDA granted Qualified Infectious Disease Product (QIDP) designation to XF-73 from Destiny to prevent postsurgical Staphylococcus aureus infection, including methicillin-resistant S. aureus (MRSA). The...